Korean J Physiol Pharmacol.
2011 Apr;15(2):95-100. 10.4196/kjpp.2011.15.2.95.
Regulation of DREAM Expression by Group I mGluR
- Affiliations
-
- 1Department of Pharmacology, Yonsei University College of Medicine, Seoul 120-752, Korea. kimhoon@yuhs.ac
- 2Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul 120-752, Korea.
- 3Division of Metabolic Disease, Department of Biomedical Science, National Institutes of Health, Osong 363-951, Korea.
- 4Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 120-752, Korea.
- KMID: 2285413
- DOI: http://doi.org/10.4196/kjpp.2011.15.2.95
Abstract
- DREAM (downstream regulatory element antagonistic modulator) is a calcium-binding protein that regulates dynorphin expression, promotes potassium channel surface expression, and enhances presenilin processing in an expression level-dependent manner. However, no molecular mechanism has yet explained how protein levels of DREAM are regulated. Here we identified group I mGluR (mGluR1/5) as a positive regulator of DREAM protein expression. Overexpression of mGluR1/5 increased the cellular level of DREAM. Up-regulation of DREAM resulted in increased DREAM protein in both the nucleus and cytoplasm, where the protein acts as a transcriptional repressor and a modulator of its interacting proteins, respectively. DHPG (3,5-dihydroxyphenylglycine), a group I mGluR agonist, also up-regulated DREAM expression in cortical neurons. These results suggest that group I mGluR is the first identified receptor that may regulate DREAM activity in neurons.
